Higher iron in the red nucleus marks Parkinson's dyskinesia

Neurobiology of Aging

Volumn 34, Issue 5, 2013, Pages 1497-1503

  Lewis, Mechelle M ^a   Du, Guangwei ^a   Kidacki, Michal ^a   Patel, Nisargkumar ^a   Shaffer, Michele L ^a   Mailman, Richard B ^a   Huang, Xuemei ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

); Magnetic resonance imaging (MRI); Parkinson's disease (PD); Red nucleus; Transverse relaxation rate (R2

Indexed keywords

IRON; LEVODOPA;

ADULT; AGE DISTRIBUTION; ARTICLE; BRAIN LEVEL; BRAIN REGION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; DYSKINESIA; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; RED NUCLEUS; SEX DIFFERENCE; SUBSTANTIA NIGRA;

BIOLOGICAL MARKERS; FEMALE; HUMANS; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PARKINSON DISEASE; RED NUCLEUS; TISSUE DISTRIBUTION;

EID: 84873469778     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.10.025     Document Type: Article

References (47)

1. Baldereschi M., Di Carlo A., Rocca W.A., Vanni P., Maggi S., Perissinotto E., Grigoletto F., Amaducci L., Inzitari D. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000, 55:1358-1363.
2. Bastian A.J. Learning to predict the future: the cerebellum adapts feedforward movement control. Curr. Opin. Neurobiol. 2006, 16:645-649.
3. Beard J. Iron deficiency alters brain development and functioning. J. Nutr. 2003, 133:1468S-1472S.
4. Beard J.L., Connor J.R., Jones B.C. Iron in the brain. Nutr. Rev. 1993, 51:157-170.
5. Belhaj-Saif A., Cheney P.D. Plasticity in the distribution of the red nucleus output to forearm muscles after unilateral lesions of the pyramidal tract. J. Neurophysiol. 2000, 83:3147-3153.
6. Bird T.D., Shaw C.M. Progressive myoclonus and epilepsy with dentatorubral degeneration: a clinicopathological study of the Ramsay Hunt syndrome. J. Neurol. Neurosurg. Psychiatry 1978, 41:140-149.
7. Bostan A.C., Dum R.P., Strick P.L. The basal ganglia communicate with the cerebellum. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8452-8456.
8. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
9. Brusa L., Ceravolo R., Kiferle L., Monteleone F., Iani C., Schillaci O., Stanzione P., Koch G. Metabolic changes induced by theta burst stimulation of the cerebellum in dyskinetic Parkinson's disease patients. Parkinsonism Relat. Disord. 2011, 18:59-62.
10. Calne D.B., Snow B.J., Lee C. Criteria for diagnosing Parkinson's disease. Ann. Neurol. 1992, 32:S125-S127.
11. Cerasa A., Hagberg G.E., Peppe A., Bianciardi M., Gioia M.C., Costa A., Castriota-Scanderbeg A., Caltagirone C., Sabatini U. Functional changes in the activity of cerebellum and frontostriatal regions during externally and internally timed movement in Parkinson's disease. Brain Res. Bull. 2006, 71:259-269.
12. Drayer B., Burger P., Darwin R., Riederer S., Herfkens R., Johnson G.A. MRI of brain iron. AJR Am. J. Roentgenol. 1986, 147:103-110.
13. Du G., Lewis M.M., Styner M., Shaffer M.L., Sen S., Yang Q.X., Huang X. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov. Disord. 2011, 26:1627-1632.
14. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa-induced dyskinesias. Mov. Disord. 2007, 22:1379-1389.
15. Fuente-Fernandez R., Schulzer M., Kuramoto L., Cragg J., Ramachandiran N., Au W.L., Mak E., McKenzie J., McCormick S., Sossi V., Ruth T.J., Lee C.S., Calne D.B., Stoessl A.J. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann. Neurol. 2011, 69:803-810.
16. Gelman N., Gorell J.M., Barker P.B., Savage R.M., Spickler E.M., Windham J.P., Knight R.A. MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 1999, 210:759-767.
17. Goetz C.G., Tilley B.C., Shaftman S.R., Stebbins G.T., Fahn S., Martinez-Martin P., Poewe W., Sampaio C., Stern M.B., Dodel R., Dubois B., Holloway R., Jankovic J., Kulisevsky J., Lang A.E., Lees A., Leurgans S., LeWitt P.A., Nyenhuis D., Olanow C.W., Rascol O., Schrag A., Teresi J.A., van Hilten J.J., LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 2008, 23:2129-2170.
18. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995, 45:1138-1143.
19. Habas C., Cabanis E.A. Cortical projection to the human red nucleus: complementary results with probabilistic tractography at 3 T. Neuroradiology 2007, 49:777-784.
20. Hauser R.A., McDermott M.P., Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch. Neurol. 2006, 63:1756-1760.
21. Hoshi E., Tremblay L., Feger J., Carras P.L., Strick P.L. The cerebellum communicates with the basal ganglia. Nat. Neurosci. 2005, 8:1491-1493.
22. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov. Disord. 2005, 20(suppl 11):S11-S16.
23. Jellinger K.A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 1991, 14:153-197.
24. Kanagal S.G., Muir G.D. Task-dependent compensation after pyramidal tract and dorsolateral spinal lesions in rats. Exp. Neurol. 2009, 216:193-206.
25. Karlsborg M., Korbo L., Regeur L., Glad A. Duodopa pump treatment in patients with advanced Parkinson's disease. Dan. Med. Bull. 2010, 57:A4155.
26. Kishore A., Panikar D., Balakrishnan S., Joseph S., Sarma S. Evidence of functional somatotopy in GPi from results of pallidotomy. Brain 2000, 123:2491-2500.
27. Koch G., Brusa L., Carrillo F., Lo G.E., Torriero S., Oliveri M., Mir P., Caltagirone C., Stanzione P. Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease. Neurology 2009, 73:113-119.
28. Lapresle J., Hamida M.B. The dentato-olivary pathway. Somatotopic relationship between the dentate nucleus and the contralateral inferior olive. Arch. Neurol. 1970, 22:135-143.
29. Lavaute T., Smith S., Cooperman S., Iwai K., Land W., Meyron-Holtz E., Drake S.K., Miller G., Abu-Asab M., Tsokos M., Switzer R., Grinberg A., Love P., Tresser N., Rouault T.A. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 2001, 27:209-214.
30. Lei P., Ayton S., Finkelstein D.I., Spoerri L., Ciccotosto G.D., Wright D.K., Wong B.X., Adlard P.A., Cherny R.A., Lam L.Q., Roberts B.R., Volitakis I., Egan G.F., McLean C.A., Cappai R., Duce J.A., Bush A.I. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 2012, 18:291-295.
31. Lewis M.M., Du G., Sen S., Kawaguchi A., Truong Y., Lee S., Mailman R.B., Huang X. Differential involvement of striato- and cerebello-thalamo-cortical pathways in tremor- and akinetic/rigid-predominant Parkinson's disease. Neuroscience 2011, 177:230-239.
32. Lewis M.M., Slagle C.G., Smith A.B., Truong Y., Bai P., McKeown M.J., Mailman R.B., Belger A., Huang X. Task specific influences of Parkinson's disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries. Neuroscience 2007, 147:224-235.
33. Liu X., Osterbauer R., Aziz T.Z., Miall R.C., Stein J.F. Increased response to visual feedback of drug-induced dyskinetic movements in advanced Parkinson's disease. Neurosci. Lett. 2001, 304:25-28.
34. Martin W.R., Wieler M., Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008, 70:1411-1417.
35. Mayeux R., Denaro J., Hemenegildo N., Marder K., Tang M.X., Cote L.J., Stern Y. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch. Neurol. 1992, 49:492-497.
36. Nieto D., Nieto A. Neurochemical significance of the red nucleus. Bull. Clin. Neurosci. 1986, 51:89-93.
37. Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13:S13-S17.
38. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006, 5:677-687.
39. Olanow C.W., Obeso J.A., Stocchi F. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat. Clin. Pract. Neurol. 2006, 2:382-392.
40. Rivera-Mancia S., Perez-Neri I., Rios C., Tristan-Lopez L., Rivera-Espinosa L., Montes S. The transition metals copper and iron in neurodegenerative diseases. Chem. Biol. Interact. 2010, 186:184-199.
41. Sen S., Kawaguchi A., Truong Y., Lewis M.M., Huang X. Dynamic changes in cerebello-thalamo-cortical motor circuitry during progression of Parkinson's disease. Neuroscience 2009, 166:712-719.
42. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., Youdim M.B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 1988, 74:199-205.
43. Tomlinson C.L., Stowe R., Patel S., Rick C., Gray R., Clarke C.E. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov. Disord. 2010, 25:2649-2653.
44. Wolpert D.M., Miall R.C., Kawato M. Internal models in the cerebellum. Trends Cogn. Sci. 1998, 2:338-347.
45. Yu H., Sternad D., Corcos D.M., Vaillancourt D.E. Role of hyperactive cerebellum and motor cortex in Parkinson's disease. Neuroimage 2007, 35:222-233.
46. Yushkevich P.A., Piven J., Hazlett H.C., Smith R.G., Ho S., Gee J.C., Gerig G. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 2006, 31:1116-1128.
47. Zukor H., Song W., Liberman A., Mui J., Vali H., Fillebeen C., Pantopoulos K., Wu T.D., Guerquin-Kern J.L., Schipper H.M. HO-1-mediated macroautophagy: a mechanism for unregulated iron deposition in aging and degenerating neural tissues. J. Neurochem. 2009, 109:776-791.